In this video, Shirley Lee, MSN- FNP, MPH, of Skyline Urology in California, discusses an initiative from Skyline Urology in which they launched a remote UTI clinic coordinated by patient navigators and managed by urologists in order to improve patient access and reduce unnecessary ER visits. The initiative aimed to support the remote clinic in part through Chronic Care Management (CCM) reimbursements.
In the first year of the clinic, 125 patients with cystitis participated in the program, 88% of whom were able to avoid ED visits. Additionally, Skyline Urology was able to generate $25,000 in CCM reimbursement.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
2 Commerce Drive
Cranbury, NJ 08512